An prospective and observational study of comparison of efficacy and tolerability between metformin and combination of metformin and glibenclamide in the maintence therapy of type 2 diabetes mellitus in a tertiary care hospital

Abstract

Background Diabetes mellitus is one of the most common non-communicable disease world-wide. There are many groups of drugs available for the treatment of type 2 diabetes mellitus. we use these drugs as monotherapy or in combination to maintain normoglycemia. Because of paucity of published reports in the Indian literature regarding the pattern of use, efficacy, safety, tolerability of comparison of therapy of metformin and combination of metformin and glibenclamide, the present study was taken up. Objectives To study the comparison of efficacy, safety and tolerability of metformin and combination of metformin and glibenclamide in achieving normal blood glucose level in type 2 diabetes mellitus. Materials and methods 100 properly selected subjects with type 2 diabetes mellitus were included for the present study. The medication were used empirically as monotherapy or fixed dose combination, OD or BID in a continuation manner after the meals. Blood glucose level was measured at the baseline and daily afterwards for one month using standard techniques. The data collected was analyzed statistically using descriptive statistics. Tolerability and patient compliance for the prescribed medications were also assessed during the follow up visits. Results Combination therapy reported to control the blood glucose level more efficiently as compared to metformin monotherapy at the end of the study, as 96% of subjects showed normoglycemia as compared to metformin (70%). Also, incidence of hyperglycemic episodes were less in combination therapy. Subjects with combination therapy reported more side effects compared to metformin alone therapy. The patient compliance for the prescribed medications was excellent. Interpretation and Conclusion Blood glucose level can be effectively maintained under normal limits in Type 2 DM, with combination therapy as compared to monotherapy of metformin.

Authors and Affiliations

Dr. Syed Wasif

Keywords

Related Articles

The study on effect of self auditing the prescriptions in a polyclinic

Introduction Prescription audit help us to monitor, evaluate and suggest necessary modifications in the prescribing practices to improve the quality of prescriptions. Our objective was to do the prescription audit of pa...

Primary sclerosing cholangitis- a comprehensive review and update

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterised by inflammation and fibrosis of the biliary tree. The aim of this review is to find out the cause, symptoms, a...

A case report on management of coronary artery disease

During the past decade, major improvements in the management of Acute Myocardial Infarction (AMI) patients have reduced AMI-related mortality by 50% in developed countries. Specifically, the introduction of intensive car...

The study of prescription pattern in respiratory tract infection diseases in a tertiary care hospital

Introduction A respiratory tract infection is an infection anywhere in the respiratory tract (i.e nose, throat, lungs). The infection can be caused by bacteria, viruses or fungi. Respiratory infections are very common....

Medication Adherence Pattern Of Hypertensive Patients In Rural Area

AIM & OBJECTIVES The study investigated the level of drug adherence among hypertensive patients at a tertiary care hospital in Erode, Tamil Nadu. Specific objectives included measurement of blood pressure (BP) control a...

Download PDF file
  • EP ID EP413209
  • DOI -
  • Views 137
  • Downloads 0

How To Cite

Dr. Syed Wasif (2018). An prospective and observational study of comparison of efficacy and tolerability between metformin and combination of metformin and glibenclamide in the maintence therapy of type 2 diabetes mellitus in a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP), 7(1), 69-79. https://europub.co.uk./articles/-A-413209